Navigation Links
Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
Date:4/4/2012

WATERTOWN, Mass., April. 4, 2012 /PRNewswire/ --Enanta Pharmaceuticals, Inc., a research and development company dedicated to creating best-in-class small molecule drugs in the infectious disease field, announced today that key data from two of its hepatitis C (HCV) programs will be presented at the International Liver Congress™ 2012 (ILC2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain.  Oral presentations will discuss Phase 2 results from "Pilot" and "Co-Pilot", which investigated two different interferon-free combination regimens containing ABT-450, the lead candidate from Enanta's collaborative HCV protease inhibitor program with Abbott.  ABT-450 will be included in two additional poster presentations and a third poster presentation will report in vitro data from Enanta's proprietary nucleotide HCV polymerase inhibitor program. Abstracts are available at www.easl.eu.  

Phase 2 Data Highlights

In the study known as "Co-Pilot," different doses of ABT-450/r, plus ABT-333 and ribavirin administered for 12 weeks showed sustained virological response at 12 weeks post treatment (SVR12) in 93 percent and 95 percent of treatment-naive genotype 1 (GT1) patients.  In these patients, response was independent of HCV subtype, host IL28B genotype or dose of ABT-450/r.  In addition, SVR12 was achieved in 47 percent of patients who were previous non-responders to past HCV treatment.

In a separate study, known as "Pilot", 91 percent of genotype 1 infected, treatment-naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks (SVR24).

"The results from Pilot and Co-Pilot showed very encouraging levels of sustained response and suggest that ABT-450 could be an important component in new
'/>"/>

SOURCE Enanta Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
2. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
3. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
4. Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
5. Enanta Enters Into Strategic Collaboration to Advance NS5A Inhibitor Candidate for HCV
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 Research and Markets ... Ophthalmic Diagnostic Devices Market 2014-2018" report to their ... About Ophthalmic Diagnostic Device An ... identify a defect or deficiency in the human visual ... disorders such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, ...
(Date:7/25/2014)... 2014 NOT FOR RELEASE, PUBLICATION OR ... INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD ... SUCH JURISDICTION AbbVie (NYSE: ABBV ) today announced ... "This was another very strong quarter for ... our original guidance and announced plans to merge with Shire, ...
(Date:7/24/2014)... 24, 2014  PTC Therapeutics, Inc. (NASDAQ: ... a webcast conference call to report its second quarter ... company,s business and outlook on Thursday, August 7, 2014 ... market. The call can be accessed ... five minutes prior to the start of the call ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35
... N.C., Jan. 26, 2011 MedCath Corporation (Nasdaq: ... closes on February 9, 2011 to announce results from its ... MedCath has elected not to host a conference call to ... Corporation, headquartered in Charlotte, N.C., is a healthcare provider focused ...
... 2011 Boston Scientific Corporation (NYSE: BSX ... the PLATINUM China clinical trial, which is designed to ... Element™ Everolimus-Eluting Platinum Chromium Coronary Stent compared to the ... patients with a single de novo atherosclerotic ...
Cached Medicine Technology:Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Elementâ„¢ Everolimus-Eluting Stent 2Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Elementâ„¢ Everolimus-Eluting Stent 3Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Elementâ„¢ Everolimus-Eluting Stent 4
(Date:7/25/2014)... USA (PRWEB) July 25, 2014 As reported ... Battlefield in War On Heroin (7/20), police in Salem, ... seriously crack down on the recent heroin epidemic that has ... article focuses on one heroin-related overdose case in which police ... in the victim's cell phone. By pretending to be the ...
(Date:7/25/2014)... Consuming too much salt? Overloaded on fats, sugars ... labels! , Learn to decipher the valuable information on ... during a "Healthy Eating for You: Label Reading" presentation ... Ohltown Road, Austintown. , Registered dietician and community educator ... questions. , The presentation is free and open ...
(Date:7/25/2014)... Sport Court® provided and ... Nike National Invitational Tournament (NIT) in Chicago at ... National Tournament (USJN) in Washington D.C. at the ... these prestigious national tournaments included 44 Sport Court Maple ... playing surface at McCormick Place for the NIT, and ...
(Date:7/25/2014)... 2014 As reported by People Magazine in ... Jersey Shore and Getting Sober (7/15), one of the ... has spoken out to the public about his personal transformation. ... The Situation admits that moving on with his life was ... and other drugs in 2012 and even spent some time ...
(Date:7/25/2014)... The human brain can preserve oxygen to protect itself ... Although dehydration significantly reduces blood flow to ... brain compensates by increasing the amount of oxygen it ... us understand a lot more about how the human ... first author Steven Trangmar, a researcher at Brunel University, ...
Breaking Medicine News(10 mins):Health News:Multiple States Crack Down on Heroin Epidemic 2Health News:Learn to Decipher Food Labels at Humility House 2Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Human Brain Has Coping Mechanism for Dehydration 2
... muscle that separates the chest cavity from the abdominal ... birth defect known as congenital diaphragmatic hernia (CDH), results ... allows abdominal organs to migrate into the chest cavity. ... CDH, and in fact is the major predictor of ...
... its high court proved that collective bargaining rights are indeed ... judgment against the provincial government which was supporting the Bill ... negating union contracts, has been hailed by union and labor ... to provide labor flexibility, by the then B.C Liberal government, ...
... on lab mice slows and may even halt the progress ... rolling back this tragic disease, US researchers report on Sunday. ... blood pressure, rejuvenated ageing dopamine cells, the brain cells whose ... mice was so promising that the team now plan on ...
... that the courts are seeing a number of sex offence ... cases by these Juvenile offenders. ,Some psychologists ... decades on a society saturated with sex and violence ... victims of adult sexual predators. Others say there aren't more ...
... in rheumatoid arthritis reported at Federation of Clinical Immunology ... makes these people susceptible to the disabling inflammatory condition. ... circle between key genes identified in his laboratory at ... Genetics at The Feinstein Institute for Medical Research in ...
... with little surprises up its sleeves; one of which is ... ,According to experts, the spread of dengue, which ... in much of the region, has also accelerated in recent ... the region , So why not consider ...
Cached Medicine News:Health News:Understanding and Treating Congenital Diaphragmatic Hernia 2Health News:Understanding and Treating Congenital Diaphragmatic Hernia 3Health News:Understanding and Treating Congenital Diaphragmatic Hernia 4Health News:Fangs Taken Out of Canadas Bill 29 2Health News:Test Drug Seen as Best Hope in Decades for Tackling Parkinson's 2Health News:Younger and Violent Sex Offenders on the Rise 2Health News:New Developments in Rheumatoid Arthritis 2Health News:New Developments in Rheumatoid Arthritis 3Health News:Dengue Sweeping Across Southeast Asia 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: